PDC*line Pharma

PDC*line Pharma is a clinical-stage Biotechnology company that develops a new class of potent, off-the-shelf therapeutic cancer vaccines based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC*line). Based on a robust preclinical package and a first-in-human phase Ib in melanoma, PDC*line Pharma reported promising Phase I/II results in lung cancer (PDC*lung) in 2024. Preparations are now underway for a randomized Phase IIb trial in lung cancer, and a Phase Ib trial in colorectal cancer with neoantigens (PDC*neo). The company has raised €61M in equity and non-dilutive funding and signed a €108M licensing deal in Asia with the Korean pharmaceutical company, LG Chem Life Science.

News

PDC*line Pharma presents primary clinical results from phase I/II trial on PDC*lung01 cancer vaccine at ESMO-IO 2024

PDC*line Pharma presents primary clinical results from phase I/II trial on PDC*lung01 cancer vaccine at ESMO-IO 2024

PDC*lung01, in combination with pembrolizumab, demonstrates the potential to provide meaningful clinical benefit compared to

PDC*line Pharma has been selected for an oral presentation at the “Educational Days” of the Francophone Society of Histocompatibility and Immunogenetics (SFHI)

We are thrilled to announce that we have been selected for an oral presentation at the “Educational Days” of the Francophone Society of Histocompatibility and Immunogenetics (SFHI), held in Strasbourg from October 9 to 11, 2024!
The presentation